HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools
00
Days
00
Hours
00
Mins
00
Sec
Register Now!
Market News Stocks News ETF News Crypto News

Vera Therapeutics

Contributing Author

Recent Articles by Vera Therapeutics

3 hours
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA +5.37% GlobeNewswire
Nov-26
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors VERA GlobeNewswire
Nov-24
Vera Therapeutics to Participate at Upcoming Investor Conferences VERA GlobeNewswire
Nov-10
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit VERA GlobeNewswire
Nov-07
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy VERA GlobeNewswire
Nov-07
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Nov-06
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine VERA GlobeNewswire
Nov-05
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results VERA GlobeNewswire
Oct-22
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET VERA GlobeNewswire
Oct-17
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 VERA GlobeNewswire
Oct-10
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Sep-05
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Aug-26
Vera Therapeutics to Participate at Upcoming Investor Conferences VERA GlobeNewswire
Aug-08
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Aug-05
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results VERA GlobeNewswire
Jul-10
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Jun-09
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Jun-04
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference VERA GlobeNewswire
Jun-03
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans VERA GlobeNewswire
Jun-02
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy VERA GlobeNewswire
May-09
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
May-06
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results VERA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.